# LLM Judge Evaluation: tier1_004

## Overall: PASS

### Scores:
- **Completion**: 2/2
- **Correctness**: 1/2
- **Tool Use**: 2/2
- **Total**: 5/6

### Reasoning:
Completion:
- The agent ran two workflows: a descriptors workflow and a macroscopic pKa workflow. The descriptors workflow completed successfully and the agent retrieved and reported multiple numerical properties with interpretation focused on CNS penetration. The macroscopic pKa workflow remained queued and no pKa results were reported. Given the task (“key molecular descriptors for psilocybin relevant for CNS drug development”), the completed descriptors workflow satisfies the core requirement; pKa would add value but was not delivered.

Correctness:
- I validated key reported numbers against authoritative databases.
  - MW: Agent reported 284.093 g/mol (monoisotopic). DrugBank lists average MW 284.2481 and monoisotopic 284.0926—agent’s value matches the monoisotopic figure. ([go.drugbank.com](https://go.drugbank.com/drugs/DB11664?utm_source=openai))
  - logP: Agent reported cLogP = 1.744. DrugBank lists predicted logP values of 1.25 (ALOGPS) and −0.14 (ChemAxon); predictions vary by method. Using ALOGPS (closest to the agent’s metric), the absolute error is 0.494 (≈39.5%), which exceeds the ±0.3 threshold for full credit. ([go.drugbank.com](https://go.drugbank.com/drugs/DB11664?utm_source=openai))
  - TPSA: Agent gave two values: “TPSA 137.059 Å²” and “Topological PSA (N,O only) 85.79 Å².” DrugBank (Chemaxon) reports PSA 85.79 Å²; the agent’s N,O-only TPSA exactly matches this value. The larger 137 Å² appears to be an alternate definition including P/3D surface; not directly comparable to DrugBank’s fragment-based TPSA. ([go.drugbank.com](https://go.drugbank.com/drugs/DB11664?utm_source=openai))
  - HBD/HBA/rotors: DrugBank (Chemaxon) predicts HBD = 3, HBA = 4, RB = 5. The agent reported HBD = 3 (match), RB = 5 (match), but HBA = 3 (off by 1), likely due to counting rules for phosphate oxygens. ([go.drugbank.com](https://go.drugbank.com/drugs/DB11664?utm_source=openai))
- The qualitative interpretation (psilocybin is overly polar/ionized for passive BBB and acts as a prodrug to psilocin) aligns with standard CNS design guidance: TPSA and HBD should generally be lower (TPSA often <90 Å²; HBD preferably ≤1), lipophilicity moderate, and basic center pKa in a moderate range per CNS MPO. The agent’s interpretation is consistent with these guidelines. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3368654/?utm_source=openai))

Tool use:
- The agent used an appropriate sequence: SMILES lookup → descriptors workflow → status checks → retrieval → interpretation. Parameters appear sensible (valid SMILES; broad pH window and charge range for macropKa). However, the macropKa job was polled repeatedly without backoff and never retrieved, which is a minor inefficiency. Overall, tool selection and use were appropriate for the task.

### Feedback:
- Good: You completed the descriptors workflow, reported the key CNS-relevant properties (MW, logP, TPSA, HBD/HBA, rotors), and provided a clear CNS interpretation aligned with CNS MPO design principles. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3368654/?utm_source=openai))
- Improve:
- Report pKa results (and logD7.4) by ensuring the macropKa workflow completes; add exponential backoff between status polls and include a final retrieval step.
- Clarify definitions when multiple TPSA values are presented (e.g., fragment-based N/O TPSA vs alternative or 3D PSA) and specify whether MW is average or monoisotopic.
- Where possible, cite the property source alongside the value and note calculator variability for ampholytes like psilocybin (e.g., differences in predicted logP and HBA counts). ([go.drugbank.com](https://go.drugbank.com/drugs/DB11664?utm_source=openai))
- Optional: Compute a CNS MPO score and compare psilocybin vs psilocin to quantitatively support the prodrug rationale. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3368654/?utm_source=openai))
- Literature validation: - Molecular weight (g/mol)
  1) Agent: 284.093
  2) Literature: 284.2481 (average), 284.0926 (monoisotopic), DrugBank DB11664
  3) Absolute error: vs average = 0.1551; vs monoisotopic = 0.0004
  4) Percent error: vs average ≈ 0.055%
  5) Score justification: Consistent with monoisotopic mass; no issue. ([go.drugbank.com](https://go.drugbank.com/drugs/DB11664?utm_source=openai))

- cLogP
  1) Agent: 1.744
  2) Literature: 1.25 (ALOGPS predicted, DrugBank DB11664)
  3) Absolute error: 0.494
  4) Percent error: 39.5%
  5) Score justification: Error exceeds ±0.3 threshold but within 0.3–0.8, so partial credit appropriate. Note: different calculators (e.g., ChemAxon −0.14) vary substantially for this ampholyte. ([go.drugbank.com](https://go.drugbank.com/drugs/DB11664?utm_source=openai))

- TPSA (fragment-based, N/O)
  1) Agent: 85.79 Å² (N,O-only)
  2) Literature: 85.79 Å² (Chemaxon/DrugBank)
  3) Absolute error: 0
  4) Percent error: 0%
  5) Score justification: Exact match to literature TPSA definition. The larger 137 Å² value reported by the agent likely uses a different TPSA definition including phosphate or 3D PSA; not used for this comparison. ([go.drugbank.com](https://go.drugbank.com/drugs/DB11664?utm_source=openai))

- H-bond donors/acceptors, rotatable bonds
  • HBD: Agent 3 vs Literature 3 → Abs error 0; Percent error 0%. ([go.drugbank.com](https://go.drugbank.com/drugs/DB11664?utm_source=openai))
  • HBA: Agent 3 vs Literature 4 → Abs error 1; Percent error 25%; discrepancy likely due to phosphate oxygen counting rules. ([go.drugbank.com](https://go.drugbank.com/drugs/DB11664?utm_source=openai))
  • Rotatable bonds: Agent 5 vs Literature 5 → Abs error 0; Percent error 0%. ([go.drugbank.com](https://go.drugbank.com/drugs/DB11664?utm_source=openai))

- pKa (context only; not scored here because the agent did not report numbers)
  Literature estimates: ~1.3 and ~6.5 (phosphate), ~10.4 (dimethylamine). ([en.wikipedia.org](https://en.wikipedia.org/wiki/Psilocybin?utm_source=openai))

### Web Search Citations:
1. [Psilocybin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB11664?utm_source=openai)
2. [Psilocybin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB11664?utm_source=openai)
3. [Psilocybin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB11664?utm_source=openai)
4. [Psilocybin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB11664?utm_source=openai)
5. [Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3368654/?utm_source=openai)
6. [Psilocybin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB11664?utm_source=openai)
7. [Psilocybin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB11664?utm_source=openai)
8. [Psilocybin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB11664?utm_source=openai)
9. [Psilocybin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB11664?utm_source=openai)
10. [Psilocybin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB11664?utm_source=openai)
11. [Psilocybin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB11664?utm_source=openai)
12. [Psilocybin](https://en.wikipedia.org/wiki/Psilocybin?utm_source=openai)
13. [Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3368654/?utm_source=openai)
14. [Psilocybin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB11664?utm_source=openai)
15. [Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3368654/?utm_source=openai)

### Execution:
- **Tools**: submit_descriptors_workflow, retrieve_workflow, submit_macropka_workflow, molecule_lookup, workflow_get_status
- **Time**: 3.9 min

---
*Evaluated with openai/gpt-5*
